Homeless shelter food production: positive implications for clients and volunteers

Within the context of a longstanding project (Behavioral Activation Project in Homeless Shelters), the Shelter Farm was developed on the grounds of a homeless shelter located in a food desert. The Behavioral Activation Project, which represents a decade-long collaboration between a Professor of Psychology at the University of Dayton (Roger N. Reeb, Ph.D.) and St. Vincent de Paul (Dayton, Ohio), fosters self-sufficiency in shelter residents as they strive to overcome personal challenges and obstacles associated with homelessness. Past research shows that the Behavioral Activation Project enhances the psychological (and adaptive) functioning of shelter residents as well as the civic-related development of service-learning students who assist in implementing the Project. In 2017, Dr. Reeb (University of Dayton) established a collaboration with Ms. Mills-Wasniak (Extension Educator, The Ohio State University Extension Montgomery County) to develop the Shelter Farm at the St. Vincent de Paul Gettysburg Gateway Shelter for Men. A Memorandum of Understanding among the three collaborative entities was developed and approved. Shelter residents volunteered to work alongside service-learning students and community partners on the farm. In the first season, we harvested nearly a ton of produce – all of which was delivered to the shelter kitchen to enhance the nutrition of shelter residents. The Shelter Farm also enhanced St. Vincent de Paul’s budget for food, as we estimated wholesale value of the produce at almost $4,000. This same level of success was replicated in Shelter Farm’s second season. As we faced COVID-19 obstacles in the third season, safety protocols were approved by all three aforementioned collaborative entities, and we sustained the Shelter Farm, harvesting approximately 1500 pounds of produce for the shelters. In the first season, a graduate student in clinical psychology at the University of Dayton completed an M.A. Thesis providing preliminary evidence that, as shelter residents volunteer to work alongside students and community partners on the farm, they show decreases in state anxiety and improvements in wellness over time. This manuscript provides the following: (a) a description of the long-standing Project that provided the infrastructure for developing the Shelter Farm, (b) a description of the collaborative process underlying the initiative, the Shelter Farm itself, and the success in sustaining the Shelter Farm, even in the face of COVID-19; (c) an overview of the benefits (nutritional and psychological) of the Shelter Farm for shelter residents; and (d) plans for sustaining and expanding the Shelter Farm (and associated research)

Trastuzumab Emtansine for the Treatment of HER-2 Positive Carcinoma Ex-pleomorphic Adenoma Metastatic to the Brain: A Case Report

Background: Carcinoma Ex-pleomorphic adenoma is a malignant transformation of the common benign neoplasm of the salivary glands, “pleomorphic adenoma.” Only two cases were ever reported with brain metastases, with absence of good evidence guiding management of such cases.Case Presentation: A 61-year-old woman presenting with facial paralysis was found to have carcinoma ex-pleomorphic adenoma of the parotid gland. Twenty months after local treatment, she developed brain metastases, treated with whole brain radiation therapy. The patient then had progressive intracranial disease after the end of radiation therapy in addition to the appearance of liver metastases. Pathology showed overexpression of HER2, so she was treated with Trastuzumab Emtansine (TDM1). Follow-up imaging revealed significant decrease in the number and size of the metastatic brain lesions in keeping with a good response to TDM1 treatment.Conclusion: Prognosis of metastatic carcinoma ex-pleomorphic adenoma is very poor, and there is no clear management for such cases. We present a case of carcinoma ex-pleomorphic adenoma with brain and liver metastases with a very good response to TDM1 treatment

Disentangling the links from parental monitoring and delinquent peer exposure to youth delinquency : a longitudinal, sibling comparison analysis

Research suggests that parents and peers play an integral role in the development and prevention of antisocial behaviors (AB) like conduct problems and delinquency in youth. However, the magnitude and mechanisms of these influences have been a debated topic in the field. Consequently, it is crucial to understand how these two factors work together to influence the development of antisocial behavior. Using data from the mothers of the National Longitudinal Survey of Youth and their offspring, a longitudinal, sibling comparison design was used to examine if: (1) parental monitoring moderates the relationship between the child\u27s early delinquency and subsequent deviant peer exposure (DPE), such that the influence of early delinquency on DPE will be smaller at high levels of parental monitoring and vice versa, (2) parental monitoring has an indirect effect against delinquency via its intermediate effects (mediation) against DPE, (3) baseline delinquency has an indirect effect on later, youth delinquency, vial its intermediate effects (mediation) on DPE, and (4) parental monitoring moderates the influence of DPE on later youth delinquency such that the influence of DPE will be smaller at high levels of parental monitoring, and will be larger at low levels of monitoring. Population analyses indicated that delinquency predicted increased DPE, and DPE mediated the association between early and later delinquency. In addition, DPE and parental monitoring significantly predicted later delinquency. Sibling comparison analysis revealed a significant interaction between parental monitoring and delinquency in predicting DPE, such that the association between early delinquency and later DPE was attenuated at high levels of parental monitoring. In addition, DPE significantly mediated the association between early and later delinquency in the sibling comparison analyses. The present findings provide support for an environmentally mediated effect of DPE and suggest that parental monitoring may act to suppress the link from earlier delinquency to later DPE

Decompression of Lumbar Central Spinal Canal Stenosis Following Minimally Invasive Transforaminal Lumbar Interbody Fusion

STUDY DESIGN: This was a retrospective clinical series. OBJECTIVE: The objective of this study was to evaluate radiologic changes in central spinal canal dimensions following minimally invasive transforaminal lumbar interbody fusion (MIS-TLIF) with placement of a static or an expandable interbody device. SUMMARY OF BACKGROUND DATA: MIS-TLIF is used to treat lumbar degenerative diseases and low-grade spondylolisthesis. MIS-TLIF enables direct and indirect decompression of lumbar spinal stenosis, with patients experiencing relief from radiculopathy and neurogenic claudication. However, the effects of MIS-TLIF on the central spinal canal are not well-characterized. MATERIALS AND METHODS: We identified patients who underwent MIS-TLIF for degenerative lumbar spondylolisthesis and concurrent moderate to severe spinal stenosis. We selected patients who had both preoperative and postoperative magnetic resonance imaging (MRI) and upright lateral radiographs of the lumbar spine. Measurements on axial T2-weighted MRI scans include anteroposterior and transverse dimensions of the dural sac and osseous spinal canal. Measurements on radiographs include disk height, neural foraminal height, segmental lordosis, and spondylolisthesis. We made pairwise comparisons between each of the central canal dimensions and lumbar sagittal segmental radiologic outcome measures relative to their corresponding preoperative values. Correlation coefficients were used to quantify the association between changes in lumbar sagittal segmental parameters relative to changes in radiologic outcomes of central canal dimensions. Statistical analysis was performed for all patients and further stratified by interbody device subgroups (static and expandable). RESULTS: Fifty-one patients (age 60.4 y, 68.6% female) who underwent MIS-TLIF at 55 levels (65.5% at L4-L5) were included in the analysis. Expandable interbody devices were used in 45/55 (81.8%) levels. Mean duration from surgery to postoperative MRI scan was 16.5 months (SD 11.9). MIS-TLIF was associated with significant improvements in dural sac dimensions (anteroposterior +0.31 cm, transverse +0.38 cm) and osseous spinal canal dimensions (anteroposterior +0.16 cm, transverse +0.32 cm). Sagittal lumbar segmental parameters of disk height (+0.56 cm), neural foraminal height (+0.35 cm), segmental lordosis (+4.26 degrees), and spondylolisthesis (-7.5%) were also improved following MIS-TLIF. We did not find meaningful associations between the changes in central canal dimensions relative to the corresponding changes in any of the sagittal lumbar segmental parameters. Stratified analysis by interbody device type (static and expandable) revealed similar within-group changes as in the overall cohort and minimal between-group differences. CONCLUSIONS: MIS-TLIF is associated with radiologic decompression of neural foraminal and central spinal canal stenosis. The mechanism for neural foraminal and central canal decompression is likely driven by a combination of direct and indirect corrective techniques

The radioscience LaRa instrument onboard ExoMars 2020 to investigate the rotation and interior of mars

LaRa (Lander Radioscience) is an experiment on the ExoMars 2020 mission that uses the Doppler shift on the radio link due to the motion of the ExoMars platform tiedto the surface of Mars with respect to the Earth ground stations (e.g. the deep space network stations of NASA), in order to precisely measure the relative velocity of thelander on Mars with respect to the Earth. The LaRa measurements shall improve the understanding of the structure and processes in the deep interior of Mars byobtaining the rotation and orientation of Mars with a better precision compared to the previous missions. In this paper, we provide the analysis done until now for thebest realization of these objectives. We explain the geophysical observation that will be reached with LaRa (Length-of-day variations, precession, nutation, andpossibly polar motion). We develop the experiment set up, which includes the ground stations on Earth (so-called ground segment). We describe the instrument, i.e.the transponder and its three antennas. We further detail the link budget and the expected noise level that will be reached. Finally, we detail the expected results,which encompasses the explanation of how we shall determine Mars' orientation parameters, and the way we shall deduce Mars' interior structure and Mars’at-mosphere from them. Lastly, we explain briefly how we will be able to determine the Surface platform position

GWAS and meta-analysis identifies 49 genetic variants underlying critical COVID-19

Data availability: Downloadable summary data are available through the GenOMICC data site (https://genomicc.org/data). Summary statistics are available, but without the 23andMe summary statistics, except for the 10,000 most significant hits, for which full summary statistics are available. The full GWAS summary statistics for the 23andMe discovery dataset will be made available through 23andMe to qualified researchers under an agreement with 23andMe that protects the privacy of the 23andMe participants. For further information and to apply for access to the data, see the 23andMe website (https://research.23andMe.com/dataset-access/). All individual-level genotype and whole-genome sequencing data (for both academic and commercial uses) can be accessed through the UKRI/HDR UK Outbreak Data Analysis Platform (https://odap.ac.uk). A restricted dataset for a subset of GenOMICC participants is also available through the Genomics England data service. Monocyte RNA-seq data are available under the title ‘Monocyte gene expression data’ within the Oxford University Research Archives (https://doi.org/10.5287/ora-ko7q2nq66). Sequencing data will be made freely available to organizations and researchers to conduct research in accordance with the UK Policy Framework for Health and Social Care Research through a data access agreement. Sequencing data have been deposited at the European Genome–Phenome Archive (EGA), which is hosted by the EBI and the CRG, under accession number EGAS00001007111.Extended data figures and tables are available online at https://www.nature.com/articles/s41586-023-06034-3#Sec21 .Supplementary information is available online at https://www.nature.com/articles/s41586-023-06034-3#Sec22 .Code availability: Code to calculate the imputation of P values on the basis of SNPs in linkage disequilibrium is available at GitHub (https://github.com/baillielab/GenOMICC_GWAS).Acknowledgements: We thank the members of the Banco Nacional de ADN and the GRA@CE cohort group; and the research participants and employees of 23andMe for making this work possible. A full list of contributors who have provided data that were collated in the HGI project, including previous iterations, is available online (https://www.covid19hg.org/acknowledgements).Change history: 11 July 2023: A Correction to this paper has been published at: https://doi.org/10.1038/s41586-023-06383-z. -- In the version of this article initially published, the name of Ana Margarita Baldión-Elorza, of the SCOURGE Consortium, appeared incorrectly (as Ana María Baldion) and has now been amended in the HTML and PDF versions of the article.Copyright © The Author(s) 2023, Critical illness in COVID-19 is an extreme and clinically homogeneous disease phenotype that we have previously shown1 to be highly efficient for discovery of genetic associations2. Despite the advanced stage of illness at presentation, we have shown that host genetics in patients who are critically ill with COVID-19 can identify immunomodulatory therapies with strong beneficial effects in this group3. Here we analyse 24,202 cases of COVID-19 with critical illness comprising a combination of microarray genotype and whole-genome sequencing data from cases of critical illness in the international GenOMICC (11,440 cases) study, combined with other studies recruiting hospitalized patients with a strong focus on severe and critical disease: ISARIC4C (676 cases) and the SCOURGE consortium (5,934 cases). To put these results in the context of existing work, we conduct a meta-analysis of the new GenOMICC genome-wide association study (GWAS) results with previously published data. We find 49 genome-wide significant associations, of which 16 have not been reported previously. To investigate the therapeutic implications of these findings, we infer the structural consequences of protein-coding variants, and combine our GWAS results with gene expression data using a monocyte transcriptome-wide association study (TWAS) model, as well as gene and protein expression using Mendelian randomization. We identify potentially druggable targets in multiple systems, including inflammatory signalling (JAK1), monocyte–macrophage activation and endothelial permeability (PDE4A), immunometabolism (SLC2A5 and AK5), and host factors required for viral entry and replication (TMPRSS2 and RAB2A).GenOMICC was funded by Sepsis Research (the Fiona Elizabeth Agnew Trust), the Intensive Care Society, a Wellcome Trust Senior Research Fellowship (to J.K.B., 223164/Z/21/Z), the Department of Health and Social Care (DHSC), Illumina, LifeArc, the Medical Research Council, UKRI, a BBSRC Institute Program Support Grant to the Roslin Institute (BBS/E/D/20002172, BBS/E/D/10002070 and BBS/E/D/30002275) and UKRI grants MC_PC_20004, MC_PC_19025, MC_PC_1905 and MRNO2995X/1. A.D.B. acknowledges funding from the Wellcome PhD training fellowship for clinicians (204979/Z/16/Z), the Edinburgh Clinical Academic Track (ECAT) programme. This research is supported in part by the Data and Connectivity National Core Study, led by Health Data Research UK in partnership with the Office for National Statistics and funded by UK Research and Innovation (grant MC_PC_20029). Laboratory work was funded by a Wellcome Intermediate Clinical Fellowship to B.F. (201488/Z/16/Z). We acknowledge the staff at NHS Digital, Public Health England and the Intensive Care National Audit and Research Centre who provided clinical data on the participants; and the National Institute for Healthcare Research Clinical Research Network (NIHR CRN) and the Chief Scientist’s Office (Scotland), who facilitate recruitment into research studies in NHS hospitals, and to the global ISARIC and InFACT consortia. GenOMICC genotype controls were obtained using UK Biobank Resource under project 788 funded by Roslin Institute Strategic Programme Grants from the BBSRC (BBS/E/D/10002070 and BBS/E/D/30002275) and Health Data Research UK (HDR-9004 and HDR-9003). UK Biobank data were used in the GSMR analyses presented here under project 66982. The UK Biobank was established by the Wellcome Trust medical charity, Medical Research Council, Department of Health, Scottish Government and the Northwest Regional Development Agency. It has also had funding from the Welsh Assembly Government, British Heart Foundation and Diabetes UK. The work of L.K. was supported by an RCUK Innovation Fellowship from the National Productivity Investment Fund (MR/R026408/1). J.Y. is supported by the Westlake Education Foundation. SCOURGE is funded by the Instituto de Salud Carlos III (COV20_00622 to A.C., PI20/00876 to C.F.), European Union (ERDF) ‘A way of making Europe’, Fundación Amancio Ortega, Banco de Santander (to A.C.), Cabildo Insular de Tenerife (CGIEU0000219140 ‘Apuestas científicas del ITER para colaborar en la lucha contra la COVID-19’ to C.F.) and Fundación Canaria Instituto de Investigación Sanitaria de Canarias (PIFIISC20/57 to C.F.). We also acknowledge the contribution of the Centro National de Genotipado (CEGEN) and Centro de Supercomputación de Galicia (CESGA) for funding this project by providing supercomputing infrastructures. A.D.L. is a recipient of fellowships from the National Council for Scientific and Technological Development (CNPq)-Brazil (309173/2019-1 and 201527/2020-0)